Skip to main content
  • Saved

made a Post

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

Source :

https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa649/5922803

Elevated baseline levels of lipoprotein(a), a genetically determined low-density lipoprotein particle, have been associated with increased risk of cardiovascular events in epidemiological studies and Mendelian randomization analyses., In keeping with these observations, recent updates to the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) lipid guidelines have highlighted